Table 2 Features of population included in RCTs
Population | N = 40 |
|---|---|
Age | |
Adults and seniors (adults > 65 years) | 33 (82.5) |
Adults (18 to 65 years) | 2 (5) |
All ages | 4 (10) |
Children | 1 (2.5) |
Disease | |
GPA + MPA (± renal limited AAV) | 20 (50) |
only GPA | 6 (15) |
GPA + MPA + EGPA (± renal limited AAV) | 5 (12.5) |
only EGPA | 3 (7.5) |
only MPA | 2 (5) |
AAV with other vasculitides/autoimmune diseases | 4 (10) |
Diagnosis status | |
Newly diagnosed and/or prevalent patients | 31 (77.5) |
Prevalent patients | 6 (15) |
Newly diagnosed patients | 3 (7.5) |
Classification criteria used to include patients | |
Chapel-Ill nomenclature | 6 (15) |
Revised Chapel-Ill nomenclature | 3 (7.5) |
ACR criteria | 5 (12.5) |
Chapel-Hill nomenclature and/or ACR criteria ± other | 3 (7.5) |
Clinical diagnosis or not specified | 19 (47.5) |
Other | 4 (10) |
Main treatment indication | |
Induction of remission | 16 (40) |
Maintenance of remission | 13 (32.5) |
Induction and maintenance of remission | 4 (10) |
Other | 7 (17.5) |
Classification of important outcomes | |
Patients important outcomes (PIO) | 37/43* (85) |
Surrogate outcomes (SO) | 6/43* |
No. of studies with at least one PIO as primary outcome | 33 (82.5) |
Glucocorticoids dose/use included in primary outcome | 11/43* (25%) |
Glucocorticoids dose/use as the only primary outcome | 2/43* |